Knowledge And Prescribing Practices Regarding SSRI Antidepressants.

[Guest guest]

Note: This message is in NO WAY to be construed as a

possible endorsement of SSRI's or ANY psychotropic

medication. It is posted here only as an example of

how uninformed the people are, who are dispensing this

stuff, ie. the so called experts and guradians of your

health. This guy is an M.D. who is still very biased

and has tunnel vision, just not as bad as most. Also, please see note at the

very end of this message.

 

*******************************************************

 

> JustSayNo

> Wed, 4 Aug 2004 22:21:26 -0400

 

> [sSRI-Research] The Underlying Cause of

> Suicides and Homicides with SSRI Antidepressants:Is

> It the Drugs, the Doctors, or the Drug Companies?

>

>

> " Informed consent can be effectively exercised only

> if the patient possesses

> enough information to enable an intelligent choice

> (AMA, 1999). "

>

>

http://www.medicationsense.com/articles/april_june_04/underlying_cause.html

>

> The Underlying Cause of Suicides and Homicides with

> SSRI Antidepressants:

> Is It the Drugs, the Doctors, or the Drug Companies?

> How a dysfunctional medical-pharmaceutical complex

> causes and perpetuates

> unnecessary harm.

>

> Reports of unusual, severe reactions with

> selective serotonin reuptake

> inhibitor antidepressant drugs (SSRIs) emerged soon

> after the first SSRI,

> Prozac, was introduced in 1988. One of my own

> patients, a woman with a mild

> depressive disorder and no history of major

> psychiatric symptoms, became

> psychotic after just three days on Prozac. Another

> woman, a highly

> successful attorney, developed such severe panic

> attacks that she couldn't

> work. Such cases were reported so frequently that

> Congress held hearings on

> the issue in the early 1990s. But because the

> hearings got no further than

> arguing whether SSRIs cause suicidal and homicidal

> behavior or not, and

> never looked at the underlying causes, nothing was

> accomplished.

>

> I have never doubted that SSRIs (Prozac, Paxil,

> Zoloft, Celexa,

> Lexapro, Luvox, Effexor, Sarafem) can provoke

> impulsive, violent behavior.

> Now, sixteen years after the first reports, British

> regulatory authorities

> have acted against the use of SSRIs in children

> because of an increased

> incidence of suicide. This forced the U.S. Food and

> Drug Administration to

> take a second look. In early February 2004, a FDA

> advisory committee heard

> powerful testimony from bereaved parents and medical

> experts and issued a

> call for stronger warnings on the labels of these

> drugs. The FDA is

> considering it.

>

> Even if the FDA acts, will such warnings make

> any difference? Not

> likely. As the FDA has learned, adding warnings to

> package inserts does

> little to improve how doctors prescribe drugs.1-3

> Doctors kept prescribing

> Rezulin and Seldane inappropriately despite added

> warnings, and patients

> continued dying until the drugs were withdrawn.

> About 20% of all medications

> ultimately require additional " black-box " warnings

> about dangerous side

> effects discovered after the drugs' approvals,1 yet

> despite these additional

> warnings, doctors' prescribing methods remain poor

> and the incidence of

> medication-caused hospitalizations and deaths

> remains high.

>

> Merely adding warnings to package inserts is

> inadequate because once

> doctors begin prescribing a drug, they don't read

> every updated package

> insert of every drug they use. Doing so would take

> hours, and package

> inserts are long and written in tiny, barely

> readable script, so new

> warnings are easily overlooked.

> Moreover, it usually takes years for such warnings

> to be added to package

> inserts, during which time doctors continue

> prescribing the drugs to

> millions of people. The fact is, most doctors rely

> on information provided

> by the drug companies' legions of sales

> representatives who accentuate the

> positive and downplay the negative.

>

> What should be done? The answer is obvious:

> look at why these reactions

> are occurring and impose appropriate solutions.

>

> My book, Over Dose: The Case Against The Drug

> Companies (Tarcher/Putnam

> 2001)4 laid it out and, for doing so, received

> excellent reviews including

> the recommendation of the Journal of the American

> Medical Association. Here

> is a more succinct explanation of why good drugs

> cause so much unnecessary

> harm, and why the medical-pharmaceutical complex

> allows it to happen again

> and again.

>

> The Drug Companies

>

> First rule: it's all about sales. Making

> profits is the overriding

> ethic of pharmaceutical companies. What maximizes

> sales? Marketing that

> impresses doctors. Although patients like you take

> the medications, pay the

> pharmacies, and take the risks, it is doctors who

> decide which drug and what

> dosage is used. Doctors are the final decision

> makers, and once a

> prescription is written, you have no say in the

> matter. If your doctor

> prescribes 50 mg of Zoloft for you, you cannot tell

> your pharmacist to give

> you a lower dosage or that you want to get Paxil or

> Effexor instead.

>

> Doctors determine which drugs will succeed and

> which will fail. Drug

> companies know this and know how to impress doctors

> with: 1) claims of

> superior effectiveness; 2) easy-to-use drugs.

> Superior effectiveness means

> being able to claim that your drug is better than

> its competitors in some

> way. It's very helpful, for example, for a drug

> company to be able to boast

> that " our drug helps 72% of patients, yet our

> competitor's helps only 64%. "

> Although these numbers may have little meaning when

> it comes to treating

> individuals, the numbers impress doctors. To achieve

> superior numbers, drug

> companies use stronger and stronger drug doses in

> their studies in order to

> elicit any little advantage over competitors that

> they can then market

> vigorously to doctors. They publish the studies they

> want the healthcare

> community to see and untold the ones they don't.

>

> Drug companies also know that doctors like

> drugs that are easy to

> prescribe. One-size-fits-all drugs fit the bill,

> because their dosages are

> easy to remember and doctors don't have to take the

> time to select different

> doses for different patients. This goes against the

> basic medical principle

> of individual variation: that different people

> require and tolerate

> different doses of medications (just as with coffee

> and alcohol). But such

> methods allow drug companies to promote their drugs

> with such boasts as " no

> adjustment needed for the elderly, " as if that's a

> good thing. It isn't --

> older people almost always require much lower drug

> doses -- but most doctors

> unquestioningly accept drug company guidelines.

>

> Today's pharmaceutical industry marketing

> strategy is: Make it strong

> and keep it simple. This is why Prozac was

> introduced with a

> one-size-fits-all starting dose of 20 mg, even

> though the manufacturer knew

> that 54% of patients responded to just 5 mg, a

> 75%-lower dose that caused

> fewer side effects.5 Other SSRIs with unnecessarily

> strong starting doses

> soon followed.

>

> Strong drug doses work for some people, but

> they are a sure-fire recipe

> for major side effects in others, yet the drug

> companies develop drug after

> drug in this manner. This is why SSRIs cause sexual

> dysfunctions in as many

> as 50% of patients.6-8 Side effects such as anxiety,

> agitation (akathisia),

> insomnia, and panic attacks are common and can

> become so severe that they

> impair cognitive functioning and judgment, leading

> to impulsive, destructive

> behavior by people who never acted in such a way

> before.9-13

>

> Doctors and SSRI Antidepressants

>

> Patients have the mistaken impression that

> doctors understand SSRI

> drugs. Most doctors don't.

> The drug companies have marketed SSRI

> antidepressants vigorously not

> only to psychiatrists, who are supposed to have some

> expertise with these

> drugs, but also to family practitioners,

> pediatricians, gynecologists,

> internal medicine specialists, and anyone else who

> can pen a prescription.

> But this doesn't mean that they possess in-depth

> knowledge of SSRIs or their

> actions and toxicities. Many doctors don't know the

> difference between major

> and minor (dysthymic) depressions and that the

> latter responds to much lower

> SSRI doses. Many doctors don't understand bipolar

> (manic-depressive)

> disorder and that overly strong SSRI doses can

> trigger manic reactions.

 

( Moderator's Note: The Benzodiazapines, like valium,

xanax, etc. are very dangerous. )

 

>

> Even worse, many doctors think SSRIs are the

> best treatment for anxiety

> symptoms. They aren't. For immediate relief of

> anxiety, Xanax, Valium, and

> other benzodiazepines are fast-acting and safe if

> used in moderation. SSRIs

> have no immediate anxiety-reducing effects. To the

> contrary, they can

> actually provoke anxiety. SSRIs also frequently

> cause insomnia that is so

> intractable, doctors prescribe sleep-enhancing

> drugs, further complicating

> treatment.

>

> So why do doctors prescribe SSRIs for anxiety

> symptoms? Because if

> taken for awhile -- at a low dosage -- SSRIs can

> sometimes reduce the

> development of anxiety symptoms. When used properly,

> SSRIs can help panic

> and obsessive-compulsive disorders, but such use

> means starting with a very

> low dose and explaining that the benefits may not be

> seen for weeks. Doctors

> should also explain to patients that these drugs can

> worsen anxiety

> initially. If this happens, patients should contact

> the doctor, and the

> dosage should be lowered. Do doctors actually warn

> patients about this?

> Rarely. Most doctors don't understand it themselves.

>

> Even psychiatrists are often appallingly

> ignorant about how SSRIs work.

> This was made clear in a January 5, 2004, article in

> The New York Times

> titled " A Doctor's Toxic Shock. " 14 A doctor taking

> Wellbutrin herself

> described her reaction: " I developed insomnia,

> agitation and tremors...

> panic attacks started... I needed every ounce of

> energy to concentrate at

> work.... Sometimes I felt paranoid, and I wondered

> if I was delusional. When

> I wasn't working, I was curled in a fetal position,

> contemplating whether I

> should hospitalize myself. "

>

> This was a serious reaction, exactly like those

> that drive some people

> to violence. Yet the doctor had no clue that it was

> a dose-related reaction

> to the very drug she had prescribed for herself.

> What did she do? Exactly

> what she and other doctors tell patients to do:

> stick it out until the

> drug's benefits kick in. This is ridiculous,

> dangerous advice, but it's the

> medical mainstream's party line. Indeed, the doctor

> described talking to

> colleagues, who were similarly perplexed by her

> symptoms. It is very

> disturbing to think that there are psychiatrists out

> there who can't

> recognize the most basic adverse effects of these

> antidepressants. Every

> psychiatrist I asked about this immediately

> identified the symptoms as SSRI

> side effects and recommended discontinuing the drug

> or at least decreasing

> the dosage, so at least some psychiatrists know what

> they are doing. But not

> enough, apparently.

>

> There is no excuse for not recognizing SSRI

> reactions. There is

> extensive literature on the dangers with SSRIs 9-13,

> 15-26, and anxiety and

> agitation are listed as side effects in the package

> inserts of most SSRI

> drugs and Wellbutrin (which although not an SSRI,

> can cause anxiety.) So it

> is alarming that so many intelligent, capable

> doctors are so confused when

> typical SSRI side effects develop. Yet, if these

> doctors are relying on the

> information provided by drug companies and their

> 90,000 sales reps and drug

> company-underwritten, expenses-paid seminars and

> conferences, maybe it isn't

> so surprising after all.

>

> Medical educators such as Dr. Jerry Avorn at

> Harvard and Dr. Roger

> Jelliffe at the University of Southern California

> have long sought better

> training for doctors about medications. Presently,

> most students get one

> course that broadly covers the basics on hundreds of

> drugs, but lacks any

> depth and fails to teach critical analysis. Raymond

> L. Woosley, Vice

> President of Health Services at the University of

> Arizona wrote to me:

>

> " Only about fifteen of the medical schools today

> teach formal courses in

> clinical pharmacology, which is the discipline that

> emphasizes

> interindividual variability in response to drugs.

> This small effort will

> never counter the overwhelming message from the drug

> industry that one

> dosage is all that is needed and everyone will

> respond nicely without side

> effects. " 27

>

> Dr. Woosley would like to make many changes. So

> would I. Dr. Jelliffe

> tried, but was told that medical students' schedules

> were already filled

> with more important classes. That's odd, because

> doctors' most frequent

> intervention is writing prescriptions. So what could

> be more important than

> learning to prescribe drugs properly and recognize

> side effects promptly?

>

> Meanwhile, the drug companies have penetrated

> every corner of medical

> schools and hospitals today. Medical school

> faculties and hospital staff are

> highly reliant on drug company money. The situation

> is so extreme that in

> 2000, the editor-in-chief of the New England Journal

> of Medicine published a

> disturbing yet all-too-true article titled " Is

> Academic Medicine for Sale? "

> Dr. Marcia Angell wrote:

>

> " Academic medical institutions are themselves

> growing increasingly beholden

> to [the drug] industry.... Some academic

> institutions have entered into

> partnerships with drug companies to set up research

> centers and teaching

> programs in which students and faculty members

> essentially carry out

> industry research... Young physicians learn that for

> every problem, there is

> a pill (and a drug company representative to explain

> it). " 28

>

> The drug companies are so entrenched in the

> education of medical

> students and the continuing education of doctors, it

> is no stretch for me to

> claim that we now have a " medical-pharmaceutical

> complex. " In it, doctors'

> education and information is so controlled by the

> drug industry, doctors

> don't even know how limited their information is.

> New generations of doctors

> are taught that they know everything important about

> medications, when in

> fact they don't.

>

> Thus, doctors aren't informed about obvious

> SSRI reactions and

> therefore don't warn patients. When reactions occur,

> doctors cannot identify

> them. They tell patients to stick with the drugs or

> increase the doses,

> making things worse. When patients complain about

> side effects, many doctors

> deny, deny, deny. Doctors must decide whether their

> allegiance is to their

> patients or to their medications. As I wrote in Over

> Dose, many doctors

> over-identify with their drugs, so when the drugs

> cause side effects,

> doctors get defensive rather than simply seeing side

> effects as something

> that they and their patients can solve together.

>

>

(Modrator: These drugs are pure poison. If you take

them long enough they will " bite you " in a very

serious way while also gradually damaging your organs

and overall health. )

 

> The Drugs

> Should Prozac, Paxil, Zoloft, Celexa, Lexapro,

> Luvox, Effexor, and

> Sarafem be withdrawn? Some people think so, claiming

> that SSRIs demonstrate

> no greater effectiveness than placebo.

>

> I stand squarely on the side that believes SSRI

> drugs are helpful to

> millions of people, including children. I get

> letters from people who feel

> very differently, but my experience and my reading

> of the medical literature

> convince me that SSRIs have a role in treating

> depression and other

> conditions.

>

> This isn't to say that SSRI drugs are perfect.

> Any drug that produces

> benefit can also cause harm. People vary widely in

> their responses to drugs.

> This is why it is so important to treat each person

> individually and, except

> in acute situations, to start with doses low enough

> to avoid problems. Such

> doses may be 5 mg of Prozac, 10 mg of Paxil, 25 mg

> of Zoloft, 37.5 or 75 mg

> of Effexor, etc. Some people are ultra sensitive to

> SSRIs and do well on as

> well as 2.5 mg of Prozac or 12.5 mg of Zoloft or

> equivalently tiny doses of

> other SSRIs.

>

> If after a week or two, no benefit and no side

> effects are seen, the

> doses can be gradually increased. I call this the

> " Start Low, Go Slow "

> method. By starting low and increasing gradually,

> you are guaranteed to get

> the right amount of medication for you. In this way,

> risks are minimized.

> This safety-first method is essential for side

> effect-prone drugs like

> SSRIs. Doctors should always start with low doses

> for people who are old,

> small, taking other medications, or who have a

> history of sensitivities to

> medications. But the start-low go-slow approach is

> also appropriate for

> anyone who wants to minimize medication risks.

>

> This amounts to a lot of people. When I was

> still treating patients, I

> explained the benefits and risks of antidepressants

> and asked patients

> whether they would prefer starting with a standard,

> drug company-recommended

> dose or a lower, safer, proven-effective dose. More

> than 80% preferred the

> low-dose approach. Many never needed the full drug

> company-recommended

> doses.

>

> Omitted Information = Denial of Your Right of

> Informed Consent

>

> The start-low go-slow approach make perfect

> sense and is easy to

> initiate -- if drug companies provide information

> about the lowest, safest

> drug doses in their package inserts and the

> Physicians' Desk Reference. Most

> often, they don't. Without such information, doctors

> and patients remain

> mystified when side effects strike. Many doctors

> mistake side effects for

> symptoms of the depressive disorder, and rather than

> reducing the

> medication, increase it, thereby exacerbating the

> reactions. People suffer.

> Needlessly.

>

> Information is key to inform consent. The

> American Medical Association

> Code of Medical Ethics states:

>

> " The patient's right of self-decision can be

> effectively exercised only if

> the patient possesses enough information to enable

> an intelligent choice....

> The physician has an ethical obligation to help the

> patient make choices

> from among the therapeutic alternatives consistent

> with good medical

> practice. " 29

>

> If drug companies don't provide you with

> information about the lowest,

> safest, effective drug doses, they are denying your

> right of informed

> consent. If drug companies don't give doctors full

> information about SSRI

> side effects, doctors cannot inform you, and your

> rights are further

> infringed. If doctors don't read the information

> that the drug companies do

> provide, your quality of treatment and rights of

> informed consent are again

> compromised.

>

> Studies have shown that only a small percentage of

> patients get enough

> information in doctors' offices to fulfill informed

> consent.30 With SSRI

> antidepressants, such negligence can be lethal.

>

> A Six-Point Solution

> In a recent newsletter ( " An Open Letter to the U.S.

> Food and Drug

> Administration on Serotonin-Enhancing

> Antidepressants, " Feb. 2004), I

> offered a 6-point solution to the SSRI problem:

>

> 1. Except for acute situations, patients must be

> started at the lowest,

> safest, effective doses of SSRI antidepressants.

>

> 2. Drug companies must define these doses, provide

> information in package

> inserts and the PDR, and produce pills and liquids

> that make using low doses

> possible. Drug companies must make public all of

> their data on any drug to

> be used in humans.

>

> 3. Doctors must be trained in the safe use of SSRI

> antidepressants. Classes

> and certification should be required for prescribing

> these drugs. This

> training should include some basic knowledge of

> pharmacokinetics, the

> science of drug metabolism which clearly shows that

> some patients are slow

> metabolizers of SSRIs and will develop high blood

> concentrations even with

> modest SSRI doses. If doctors understood

> pharmacogenetics better, they

> wouldn't be surprised that some people need very low

> doses of SSRIs and

> other medications.

>

> 4. Doctors must follow patients closely and warn

> patients about possible

> SSRI side effects. New patients should be seen

> frequently until doses are

> adjusted properly and side effects, if they occur,

> are handled effectively.

> Doctors should select SSRIs that come in low doses

> or as liquids, which

> allow careful, gradual dose titration.

>

> 5. Patients, including parents of children-patients,

> must be fully informed

> about the potential risks of SSRIs. Patients can

> play a critical role in

> recognizing early signs of serious side effects. The

> failure to provide

> adequate information constitutes a denial of

> patients' rights of informed

> consent and places patients at unnecessary risk.

>

> 6. The FDA must initiate policies requiring drug

> companies to develop the

> lowest, safest doses of not only SSRI

> antidepressants, but all drugs. The

> FDA must compel drug companies to add warnings to

> their package inserts

> promptly when new side effects are reported. For

> serious adverse effects

> like SSRI reactions, the FDA must compel

> manufactures to send warning

> letters to each doctor. Because even these methods

> are sometimes

> ineffective, the FDA must require doctors to report

> all SSRI reactions and

> monitor these reports closely, issuing a public

> statement every six months.

>

> What is the FDA suggesting instead? Stronger

> warnings in package

> inserts -- a strategy the FDA knows is inadequate.

>

> My 6-point solution would allow drug companies

> to continue marketing

> SSRIs, allow doctors to continue prescribing them in

> appropriate situations,

> and allow patients to obtain the benefits of SSRIs

> with minimum risk. This

> is what needs to be done not only with SSRIs, but

> with many top-selling

> drugs. But will it? Not likely in today's

> medical-pharmaceutical complex in

> which drug companies set their own prices, collect

> profits far beyond any

> other industry, and exert enormous influence on

> doctors, medical schools,

> Congress and the FDA -- and society itself.

>

> The irony is that my proposals would not only

> help patients, but

> restore some confidence in the doctor-patient

> relationship. Even the drug

> companies would benefit, because by providing better

> information about side

> effects and lower, safer medication doses, side

> effects would be fewer and,

> if occurring, would be handled properly. This is a

> much better scenario than

> today's SSRI scandal that has further tarnished the

> drug companies' image

> and hurts SSRI sales.

>

> Above all, the saddest thing about SSRI-related

> suicides and homicides

> is that they are preventable. Most side effects are

> preventable. When drugs

> and doses are matched to individual needs and

> tolerances, benefits are

> maximized and risks are minimized. Except for acute

> situations, a start-low

> go-slow approach guarantees that each person gets

> the right amount of

> medication for them, thereby reducing the frequency

> and severity of side

> effects. I've been talking about this for thirty

> years and writing about it

> for fifteen. But that's not how things are done in

> today's

> medical-pharmaceutical complex, where pharmaceutical

> sales are paramount and

> patients' safety isn't.

>

> REFERENCES

>

> 1. Lasser, KE, Alan, PD, Woolhandler, SJ,

> Himmelstein, DU, Wolfe, SM, Bor,

> DH. Timing of New Black Box Warnings and Withdrawals

> for Prescription

> Medications. JAMA 2002;287:2215-2220.

> 2. Moore, TJ, Psaty, BM, Furberg, CD. Time to act on

> drug safety. JAMA

> 1998;279(19):1571-3.

> 3. Ray, WA, Griffin, MR, Avorn, J. Evaluating Drugs

> after Their Approval for

> Clinical Use. New England Journal of Medicine

> 1993;329:2029-32.

> 4. Cohen, JS. Over Dose: The Case Against The Drug

> Companies. Prescription

> Drugs, Side Effects, and Your Health.

> Tarcher/Putnam, New York: October

> 2001.

> 5. Wernicke, JF, Dunlop, SR, Dornseif, BE, et al.

> Low-dose fluoxetine

> therapy for depression. Psychopharmacology Bulletin

> 1988;24(1):183-188.

> 6. Hirschfeld, RM. Management of sexual side effects

> of antidepressant

> therapy. Journal of Clinical Psychiatry

> 1999;60(Suppl 14):27-30.

> 7. Modell, JG, Katholi, CR, et al. Comparative

> sexual side effects of

> bupropion, fluoxetine, paroxetine, and sertraline.

> Clinical Pharmacology and

> Therapeutics 1997;61(4):476-87.

> 8. Jacobsen, FM. Fluoxetine-induced sexual

> dysfunction and an open trial of

> yohimbine. Journal of Clinical Psychiatry

> 1992;53(4):119-22.

> 9. Medawar, C, Herxheimer, A, Bell, A, et al.

> Paroxetine, Panorama, and user

> reporting of ADRs: consumer intelligence matters in

> clinical practice and

> post-marketing drug surveillance. International

> Journal of Risk & Safety in

> Medicine 2002;15:161-169.

> 10. Glenmullen, J. Prozac Backlash: Overcoming the

> Dangers of Prozac,

> Zoloft, Paxil, and Other Antidepressants with Safe,

> Effective Alternatives.

> Simon and Schuster, March 2000.

> 11. Donovan, S, Clayton, A, Beeharry, M, et al.

> Deliberate self-harm and

> antidepressant drugs. Investigation of a possible

> link. British Journal of

> Psychiatry, 2000;177:551-6.

> 12. Teicher, MH, Glod, C, Cole, JO. Emergence of

> intense suicidal

> preoccupation during fluoxetine treatment. American

> Journal of Psychiatry,

> 1990;147(2):207.

> 13. Healy, D. The Antidepressant Era. Harvard

> University Press, Sept. 1997.

> 14. Gartrell, N. A Doctor's Toxic Shock. New York

> Times, Jan. 5,

> 2003:nytimes.com

> 15. FDA statement regarding the antidepressant Paxil

> for pediatric

> population. U.S. Food and Drug Administration, June

> 19, 2003:www.fda.gov --

> accessed 9/18/O3.

> 16. Louie, AK, Lewis, TB, Lannon, MD. Use of

> low-dose fluoxetine in major

> depression and panic disorder. Journal of Clinical

> Psychiatry

> 1993;54(1):435-438.

> 17. Waechter, F. Paroxetine must not be given to

> patients under 18. BMJ,

> June 14, 2003;326:1282.

> 18. Harris, G. Debate Resumes on the Safety of

> Depression's Wonder Drugs.

> New York Times, Aug. 7, 2003:nytimes.com.

> 19. Hickling, L. Questions Persist concerning

> Prozac's Role in Suicide Risk.

> Www.drkoop.com Health News, May 11, 2000:

> www.drkoop.com/dyncon/article.asp?at=N & id=11009.

> 20. Fichter, CG, Jobe, TH, Braun, BG. Does

> fluoxetine have a therapeutic

> window? Lancet 1991;338.

> 21. Anderson GM; Segman RH; King RA. Serotonin and

> suicidality: the impact

> of fluoxetine administration. II: Acute

> neurobiological effects. Israel

> Journal of Psychiatry and Related Sciences, 1995,

> 32(1):44-50.

> 22. Lancon, C, Bernard, D, Bougerol, T. [Fluoxetine,

> akathisia and suicide].

> Encephale, 1997 May-Jun, 23(3):218-23. Abstract.

> 23. Liu, CY, Yang, YY, et al. Fluoxetine-related

> suicidality and muscle

> aches in a patient with poststroke depression

> [letter]. Journal of Clinical

> Psychopharmacology, 1996 Dec, 16(6):466-7.

> 24. Jackson, A. Drug Turned Loving Man into a

> Killer, Says Judge. Sidney

> Morning Herald, Fri., May 25, 2001:www.smh.com.au/

> 25. Donovan, S, Clayton, A, et al. Deliberate

> self-harm and antidepressant

> drugs. Investigation of a possible link. British

> Journal of Psychiatry,

> 2000;177:551-6.

> 26. Rogers, L, Waterhouse, R. Prozac Makers Told to

> Warn of Side-Effects.

> The Sunday Times [britain], July 8,

> 2001:www.sunday-times.co.uk/news.

> 27. Personal communication via email, Apr. 29, 2002,

> 4:49 EDT,

> WoosleyR.

> 28. Angell, M. Is Academic Medicine for Sale? New

> England Journal of

> Medicine 2000;342:1516-18.

> 29. American Medical Association Council on Ethical

> and Judicial Affairs.

> Code of Medical Ethics, 1998-1999 Edition. American

> Medical Association,

> Chicago, IL.

> 30. Braddock, CH, Edwards, KA, et al. Informed

> Decision Making in Outpatient

> Practice: Time to Get Back to Basics. JAMA

> 1999;282:2313-20.

> If you find this article informative, please tell

> your friends, family

> members, colleagues, and doctors about

> www.MedicationSense.com and the free

> MedicationSense E-Newsletter.

>

> Copyright 2004, Jay S. Cohen, M.D. All rights

> reserved. Readers have

> permission to copy and disseminate all or part of

> these articles if it is

> clearly identified as the work of: Jay S. Cohen,

> M.D., the MedicationSense

> E-Newsletter, www.MedicationSense.com. You may not

> use this work for

> commercial purposes.

>

> NOTE TO READERS: The purpose of this E-Letter is

> solely informational and

> educational. The information herein should not be

> considered to be a

> substitute for the direct medical advice of your

> doctor, nor is it meant to

> encourage the diagnosis or treatment of any illness,

> disease, or other

> medical problem by laypersons. If you are under a

> physician's care for any

> condition, he or she can advise you whether the

> information in this E-Letter

> is suitable for you. Readers should not make any

> changes in drugs, doses, or

> any other aspects of their medical treatment unless

> specifically directed to

> do so by their own doctors.

>

>

( Moderator's Note: Please do not stop any

psychotropic medication abruptly. It can be very

dangerous. Also, be careful about putting yourselves

into someone elses hands to get you off them. The

knowledge to get someone off these drugs is many times

more scarce even than the knowledge about them in the

first place. Educate yourselves first. Then enlist

some medical care person who will assist with YOUR

plan. 99 times out of 100, if you educate yourselves, you will know more about

the reality of the situation and how to get off them

better than they will.)